Comprehensive in vitro characterization of PD-L1 small molecule inhibitors

Blockade of the programmed cell death 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction has emerged as a powerful strategy in cancer immunotherapy. Recently, there have been enormous efforts to develop potent PD-1/PD-L1 inhibitors. In particular, Bristol-Myers Squibb (BMS) and Aurigene Dis...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Sci Rep
Autors principals: Ganesan, Aravindhan, Ahmed, Marawan, Okoye, Isobel, Arutyunova, Elena, Babu, Dinesh, Turnbull, William L., Kundu, Joydeb Kumar, Shields, Justin, Agopsowicz, Katharine Cheryl, Xu, Lai, Tabana, Yasser, Srivastava, Nutan, Zhang, Guangzhi, Moon, Tae Chul, Belovodskiy, Alexandr, Hena, Mostofa, Kandadai, Appan Srinivas, Hosseini, Seyedeh Nargess, Hitt, Mary, Walker, John, Smylie, Michael, West, Frederick G., Siraki, Arno G., Lemieux, M. Joanne, Elahi, Shokrollah, Nieman, James A., Tyrrell, D. Lorne, Houghton, Michael, Barakat, Khaled
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6712002/
https://ncbi.nlm.nih.gov/pubmed/31455818
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-48826-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars